Hims & Hers Health Inc.(NYSE:HIMS) has decided to cease offering its compounded semaglutide pill.
Hims & Hers Explains Its Decision
Hims & Hers' decision to stop offering the $49 version ofNovo Nordisk A/S'(NYSE:NVO)Wegovycomes days after the company launched it.
"Since launching the compounded semaglutide pill on our platform, we've had constructive conversations with stakeholders across the industry. As a result, we have decided to stop offering access to this treatment," the company said in a post on X.
Since launching the compounded semaglutide pill on our platform, we've had constructive conversations with stakeholders across...
Login or create a forever free account to read this news
Sign up/Log in
